In the latest session, Intellia Therapeutics Inc (NASDAQ: NTLA) closed at $27.66 up 5.98% from its previous closing price of $26.10. In other words, the price has increased by $+1.56 from its previous closing price. On the day, 1813447 shares were traded.
Ratios:
For a deeper understanding of Intellia Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.67 and its Current Ratio is at 8.67. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 23, 2024, Downgraded its rating to Neutral and sets its target price to $32 from $136 previously.
On April 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $66.Canaccord Genuity initiated its Buy rating on April 13, 2023, with a $66 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 08 when Sepp-Lorenzino Laura sold 2,275 shares for $28.87 per share. The transaction valued at 65,682 led to the insider holds 43,927 shares of the business.
LEONARD JOHN M sold 19,223 shares of NTLA for $566,310 on Jan 03. The President and CEO now owns 846,486 shares after completing the transaction at $29.46 per share. On Jan 03, another insider, Lebwohl David, who serves as the EVP, Chief Medical Officer of the company, sold 5,843 shares for $29.46 each. As a result, the insider received 172,135 and left with 54,372 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 2.66B and an Enterprise Value of 1.86B. For the stock, the TTM Price-to-Sale (P/S) ratio is 73.29 while its Price-to-Book (P/B) ratio in mrq is 2.45. Its current Enterprise Value per Revenue stands at 51.31 whereas that against EBITDA is -3.68.
Stock Price History:
Over the past 52 weeks, NTLA has reached a high of $47.48, while it has fallen to a 52-week low of $22.67. The 50-Day Moving Average of the stock is 28.00, while the 200-Day Moving Average is calculated to be 34.13.
Shares Statistics:
For the past three months, NTLA has traded an average of 1.53M shares per day and 1.8M over the past ten days. A total of 96.11M shares are outstanding, with a floating share count of 94.06M. Insiders hold about 2.12% of the company’s shares, while institutions hold 85.49% stake in the company. Shares short for NTLA as of Jan 31, 2024 were 10.97M with a Short Ratio of 7.17, compared to 10.16M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 12.25% and a Short% of Float of 13.85%.
Earnings Estimates
There are 22 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.38 for the current quarter, with a high estimate of -$1.02 and a low estimate of -$1.58, while EPS last year was -$1.17. The consensus estimate for the next quarter is -$1.28, with high estimates of -$0.98 and low estimates of -$1.68.
Analysts are recommending an EPS of between -$4.55 and -$7.03 for the fiscal current year, implying an average EPS of -$5.54. EPS for the following year is -$5.71, with 24 analysts recommending between -$4.03 and -$8.68.
Revenue Estimates
A total of 27 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $102.5M, while the lowest revenue estimate was $9M, resulting in an average revenue estimate of $53.72M. In the same quarter a year ago, actual revenue was $36.27M, up 48.10% from the average estimate.
